You can also check out everything going on by following the hashtag #GlobalScienceshow
Welcome to today's #GlobalScienceShow as part of #FUTURES2020
From now until 6pm GMT we have a new researcher every 20 minutes ready to share their work with you!
What's going on? Check out the schedule below for info on all presenters!
First up at 12.20pm is @JessieW_Palaeo
You can also check out everything going on by following the hashtag #GlobalScienceshow
If you know me, then you know I LOVE A QUIZ!!!
#FUTURES2020
https://t.co/jB6sEmP5H3
Hi, my name is Jessie Woodbridge and I'm taking part in the #GlobalScienceShow
— Jessie Woodbridge (@JessieW_Palaeo) November 28, 2020
I'll be discussing #PastEnvironmentalChanges. Follow along with the whole show and check out @JoshTylerEarth who's up next! #FUTURES2020 @GlobalSciShow pic.twitter.com/1PfM7cLQgR
@JessieW_Palaeo #FUTURES2020
It's so exciting that three new species of Gentoo penguins were recently discovered 🐧🐧🐧
#FUTURES2020
https://t.co/AFOqapN8oS
Hi, my name is Josh Tyler and I'm taking part in the #GlobalScienceShow & #FUTURES2020.
— Josh Tyler (@JoshTylerEarth) November 28, 2020
I'll be tweeting about cryptic species and how we discovered three new species of gentoo penguin\U0001f427. Follow along with the whole show and check out @Jimbo_Rand who is up next. 1/12 pic.twitter.com/4TnkM9dnDB
\U0001f44b we updated @JoshTylerEarth\u2019s voice tweet to include *automatic* captions\u2026 pic.twitter.com/NHSXF4caGQ
— HeadlinerClip Caption (@HeadlinerClip) November 28, 2020
But in reality, these amazing machines could help us monitor bodies of water much more efficiently
https://t.co/5bqkx57HLj
Hello, my name is James Rand and I am taking part in @GlobalSciShow and I will talking about lake science and underwater gliders.
— James Rand (underwater glider developer) (@Jimbo_Rand) November 28, 2020
Ask any questions that you may have and dont forget to check out Valeria Cascione who is on at 1.20pm.#FUTURES2020 #GlobalScienceShow pic.twitter.com/FpKCh0XZcJ
\U0001f44b we updated @Jimbo_Rand\u2019s voice tweet to include *automatic* captions\u2026 pic.twitter.com/44MjpKvW9A
— HeadlinerClip Caption (@HeadlinerClip) November 28, 2020
More from Science
UNEP's new Human Development Index includes a new (separate) index: Planetary pressures-adjusted HDI (PHDI). News in Norway is that its position drops from #1 to #16 because of this, while Ireland rises from #2 to #1.
Why?
https://t.co/aVraIEzRfh
Check out Norway's 'Domestic Material Consumption'. Fossil fuels are no different here to Ireland's. What's different is this huge 'non-metallic minerals' category.
(Note also the jump in 1998, suggesting data problems.)
https://t.co/5QvzONbqmN
In Norway's case, it looks like the apparent consumption equation (production+imports-exports) for non-metal minerals is dominated by production: extraction of material in Norway.
https://t.co/5QvzONbqmN
And here we see that this production of non-metallic minerals is sand, gravel and crushed rock for construction. So it's about Norway's geology.
https://t.co/y6rqWmFVWc
Norway drops 15 places on the PHDI list not because of its CO₂ emissions (fairly high at 41st highest in the world per capita), but because of its geology, because it shifts a lot of rock whenever it builds anything.
A thread on the potential near term catalysts behind why I have increased my position in 4d Pharma @4dpharmaplc (LON: #DDDD):
1) NASDAQ listing. This is the most obvious.
The idea behind this is that the huge pool of capital and institutional interest in the NASDAQ will enable a higher per-share valuation for #DDDD than was achievable in the UK.
Comparators to @4dpharmaplc #DDDD (market capitalisation £150m) on the NASDAQ and their market capitalisation:
Seres Therapeutics: $2.33bn = £1.72bn (has had a successful phase 3 C. difficile trial); from my previous research (below) the chance of #DDDD achieving this at least once is at least
While looking at speculative pharmaceutical stocks I am reminded of why I am averse to these risky picks.#DDDD was compelling enough, though, to break this rule. The 10+ treatments under trial, industry-leading IP portfolio, and comparable undervaluation are inescapable.
— Shrey Srivastava (@BlogShrey) December 16, 2020
Kaleido Biosciences: $347m = £256m. 4 products under consideration, compared to #DDDD's potential 16. When you view @4dpharmaplc's 1000+ patents and AI-driven MicroRx platform (not to mention their end-to-end manufacturing capability), 4d's undervaluation is clear.
Look like that they got a classical case of PCR Cross-Contamination.
They had 2 fabricated samples (SRX9714436 and SRX9714921) on the same PCR run. Alongside with Lung07. They did not perform metagenomic sequencing on the “feces” and they did not get
A positive oral or anal swab from anywhere in their sampling. Feces came from anus and if these were positive the anal swabs must also be positive. Clearly it got there after the NA have been extracted and were from the very low-level degraded RNA which were mutagenized from
The Taq. https://t.co/yKXCgiT29w to see SRX9714921 and SRX9714436.
Human+Mouse in the positive SRA, human in both of them. Seeing human+mouse in identical proportions across 3 different sequencers (PRJNA573298, A22, SEX9714436) are pretty straight indication that the originals
Were already contaminated with Human and mouse from the very beginning, and that this contamination is due to dishonesty in the sample handling process which prescribe a spiking of samples in ACE2-HEK293T/A549, VERO E6 and Human lung xenograft mouse.
The “lineages” they claimed to have found aren’t mutational lineages at all—all the mutations they see on these sequences were unique to that specific sequence, and are the result of RNA degradation and from the Taq polymerase errors accumulated from the nested PCR process
You May Also Like
If everyone was holding bitcoin on the old x86 in their parents basement, we would be finding a price bottom. The problem is the risk is all pooled at a few brokerages and a network of rotten exchanges with counter party risk that makes AIG circa 2008 look like a good credit.
— Greg Wester (@gwestr) November 25, 2018
The benign product is sovereign programmable money, which is historically a niche interest of folks with a relatively clustered set of beliefs about the state, the literary merit of Snow Crash, and the utility of gold to the modern economy.
This product has narrow appeal and, accordingly, is worth about as much as everything else on a 486 sitting in someone's basement is worth.
The other product is investment scams, which have approximately the best product market fit of anything produced by humans. In no age, in no country, in no city, at no level of sophistication do people consistently say "Actually I would prefer not to get money for nothing."
This product needs the exchanges like they need oxygen, because the value of it is directly tied to having payment rails to move real currency into the ecosystem and some jurisdictional and regulatory legerdemain to stay one step ahead of the banhammer.